Understanding how the Androgen Receptor influences gene activity in prostate cancer

Molecular mechanism of Androgen Receptor mediated transcription

NIH-funded research Baylor College of Medicine · NIH-11077780

This study is looking at how certain proteins, including a variant of the Androgen Receptor, affect gene activity in prostate cancer, especially when the cancer stops responding to usual treatments, with the hope of finding new ways to help patients overcome these treatment challenges.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionBaylor College of Medicine NIH-funded
Lab location1 site (Houston, United States)
Project IDNIH-11077780 on NIH RePORTER

What this research studies

This research investigates the molecular mechanisms by which the Androgen Receptor (AR) and its variant AR-V7 regulate gene expression in prostate cancer, particularly in cases that have become resistant to standard therapies. The study focuses on how AR interacts with co-regulatory proteins to form active complexes that drive transcriptional activity. By utilizing advanced imaging techniques and computational analyses, the researchers aim to uncover the unique three-dimensional arrangements of these complexes, which could lead to new therapeutic strategies targeting AR and AR-V7. Patients may benefit from insights gained into how to overcome resistance to current treatments.

Who could benefit from this research

Good fit: Ideal candidates for this research are men diagnosed with prostate cancer, especially those experiencing resistance to androgen-targeted therapies.

Not a fit: Patients with non-prostate cancers or those not affected by androgen receptor signaling may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to the development of more effective therapies for prostate cancer patients, particularly those with treatment-resistant forms of the disease.

How similar studies have performed: Previous research has shown promising results in targeting transcription factors and their co-regulators in cancer treatment, indicating that this approach has potential for success.

Where this research is happening

Houston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.